Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 9 studies | 28% ± 11% | |
non-classical monocyte | 5 studies | 23% ± 9% | |
myeloid cell | 5 studies | 20% ± 5% | |
epithelial cell | 4 studies | 23% ± 4% | |
monocyte | 4 studies | 24% ± 3% | |
regulatory T cell | 4 studies | 16% ± 1% | |
GABAergic neuron | 3 studies | 18% ± 3% | |
glutamatergic neuron | 3 studies | 25% ± 3% | |
alveolar macrophage | 3 studies | 30% ± 8% | |
lymphocyte | 3 studies | 22% ± 6% | |
microglial cell | 3 studies | 22% ± 7% |
Insufficient scRNA-seq data for expression of TRIM14 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2123.24 | 245 / 245 | 100% | 39.69 | 501 / 502 |
intestine | 100% | 2663.86 | 965 / 966 | 100% | 42.00 | 526 / 527 |
lung | 100% | 2412.44 | 577 / 578 | 100% | 33.33 | 1153 / 1155 |
esophagus | 99% | 1869.38 | 1426 / 1445 | 100% | 50.61 | 183 / 183 |
breast | 97% | 1173.22 | 447 / 459 | 99% | 44.67 | 1109 / 1118 |
stomach | 96% | 908.30 | 343 / 359 | 100% | 41.02 | 286 / 286 |
liver | 100% | 2533.41 | 226 / 226 | 95% | 19.11 | 386 / 406 |
uterus | 99% | 968.44 | 168 / 170 | 94% | 27.34 | 433 / 459 |
bladder | 95% | 1124.81 | 20 / 21 | 97% | 29.80 | 490 / 504 |
skin | 100% | 1514.99 | 1802 / 1809 | 92% | 22.70 | 435 / 472 |
kidney | 99% | 2107.54 | 88 / 89 | 91% | 28.49 | 816 / 901 |
thymus | 93% | 674.79 | 605 / 653 | 91% | 24.37 | 552 / 605 |
ovary | 80% | 543.57 | 144 / 180 | 97% | 27.28 | 415 / 430 |
brain | 82% | 717.00 | 2157 / 2642 | 93% | 23.08 | 655 / 705 |
adrenal gland | 88% | 691.34 | 226 / 258 | 70% | 14.21 | 160 / 230 |
pancreas | 37% | 192.83 | 120 / 328 | 98% | 28.60 | 174 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 43.08 | 29 / 29 |
spleen | 100% | 5758.66 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 46.43 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.77 | 1 / 1 |
peripheral blood | 98% | 2927.21 | 912 / 929 | 0% | 0 | 0 / 0 |
adipose | 96% | 1058.21 | 1158 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 71% | 9.38 | 57 / 80 |
blood vessel | 46% | 354.55 | 609 / 1335 | 0% | 0 | 0 / 0 |
heart | 21% | 107.46 | 182 / 861 | 0% | 0 | 0 / 0 |
muscle | 2% | 8.08 | 17 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0016567 | Biological process | protein ubiquitination |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0006954 | Biological process | inflammatory response |
GO_0051091 | Biological process | positive regulation of DNA-binding transcription factor activity |
GO_0032897 | Biological process | negative regulation of viral transcription |
GO_0045087 | Biological process | innate immune response |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0045335 | Cellular component | phagocytic vesicle |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0060090 | Molecular function | molecular adaptor activity |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | TRIM14 |
Protein name | Tripartite motif-containing protein 14 Tripartite motif containing 14 |
Synonyms | KIAA0129 |
Description | FUNCTION: Plays an essential role in the innate immune defense against viruses and bacteria . Promotes the 'Lys-48'-linked ubiquitination and subsequent degradation of hepatitis C virus NS5A leading to the inhibition of viral replication . Plays also a role in the inhibition of ebolavirus infection by enhancing IFN-beta and NF-kappa-B activation after binding to the viral protein NP . Facilitates the type I IFN response by interacting with MAVS at the outer mitochondria membrane and thereby recruiting NF-kappa-B essential modulator IKBKG/NEMO to the MAVS signalosome, leading to the activation of both the IFN regulatory factor 3/IRF3 and NF-kappa-B pathways . Positively regulates the CGAS-induced type I interferon signaling pathway by stabilizing CGAS and inhibiting its autophagic degradation . Acts as a scaffold between TBK1 and STAT3 to promote phosphorylation of STAT3 and resolve interferon-stimulated gene (ISG) expression . Inhibits the transcriptional activity of SPI1 in a dose-dependent manner (By similarity). Inhibits also OPTN-mediated selective autophagic degradation of KDM4D and thereby negatively regulates H3K9me2 and H3K9me3. Mechanistically, recruits USP14 to remove the 'Lys-63'-linked ubiquitination of KDM4D, preventing its recognition by OPTN and subsequent degradation . . |
Accessions | ENST00000341469.7 [Q14142-1] Q14142 ENST00000342043.3 [Q14142-1] F2Z2M2 ENST00000475147.1 ENST00000375098.7 [Q14142-1] |